Q1 2018 13F Holders as of 3/31/2018
-
Type / Class
-
Equity / Common Stock, $0.0001 Par Value Per Share
-
Shares outstanding
-
108M
-
Number of holders
-
128
-
Total 13F shares, excl. options
-
39.4M
-
Shares change
-
+956K
-
Total reported value, excl. options
-
$829M
-
Value change
-
+$31.4M
-
Put/Call ratio
-
0.54
-
Number of buys
-
57
-
Number of sells
-
-65
-
Price
-
$21.05
Significant Holders of Intra-Cellular Therapies, Inc. - Common Stock, $0.0001 Par Value Per Share (ITCI) as of Q1 2018
162 filings reported holding ITCI - Intra-Cellular Therapies, Inc. - Common Stock, $0.0001 Par Value Per Share as of Q1 2018.
Intra-Cellular Therapies, Inc. - Common Stock, $0.0001 Par Value Per Share (ITCI) has 128 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 39.4M shares
of 108M outstanding shares and own 36.55% of the company stock.
Largest 10 shareholders include FMR LLC (8.2M shares), BlackRock Inc. (3.75M shares), VANGUARD GROUP INC (3.74M shares), BB BIOTECH AG (2.2M shares), WASATCH ADVISORS INC (1.88M shares), PointState Capital LP (1.87M shares), DIMENSIONAL FUND ADVISORS LP (1.2M shares), CITADEL ADVISORS LLC (1.15M shares), PRICE T ROWE ASSOCIATES INC /MD/ (1.14M shares), and STATE STREET CORP (910K shares).
This table shows the top 128 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.